7th Apr 2021 20:00
Arix Bioscience PLC - firm which invests in biotech companies - Notes that its portfolio company Artios Pharma Ltd announced a global research collaboration with Novartis AG to discover and validate next generation DNA damage response targets to enhance Novartis' radioligand therapies. Novartis will make an up-front payment of USD20 million and provide near term research funding to support the collaboration. Artios will be eligible to receive discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of products commercialised by Novartis.
Arix is the largest shareholder in Artios, with a 12% stake.
Current stock price: 190.00 pence, up 1.1% on Wednesday
Year-to-date change: down 13%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
ARIX.L